This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalafut, M. A. Articles by Saver, J. L. Search for Related Content PubMed PubMed Citation Articles by Kalafut, M. A. Articles by Saver, J. L. Related Collections Heparin Other anticoagulants Acute Cerebral Infarction Embolic stroke Anticoagulants

(Stroke. 2000;31:2563.)
© 2000 American Heart Association, Inc.

Original Contributions

Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia

Mary A. Kalafut, MD; Rohina Gandhi, MD; Chelsea S. Kidwell, MD Jeffrey L. Saver, MD

From the Division of Neurology, Scripps Clinic, La Jolla, Calif (M.A.K.); Department of Neurology (C.S.K., J.L.S.) and Stroke Center (C.S.K., J.L.S.), University of California at Los Angeles; and Division of Neurology, Cedars Sinai Medical Center/UCLA, Los Angeles, Calif (R.G.).

Correspondence to Mary A. Kalafut, MD, 10666 N Torrey Pines Rd, MS 313, La Jolla, CA 92037. E-mail mkalafut{at}scrippsclinic.com

Background and Purpose—Anticoagulation with intravenous unfractionated heparin (IVUH) while awaiting therapeutic oral anticoagulant levels is a common practice in patients with acute and subacute cerebral ischemia. A promising alternative strategy is to use bridging subcutaneous low-molecular-weight heparin (LMWH), which may have a favorable risk-benefit profile compared with IVUH and may permit earlier discharge with completion of transition to warfarin therapy as an outpatient.

Methods—A LMWH, enoxaparin 1 mg/kg BID, was used as bridging anticoagulation therapy in 24 consecutive patients admitted to a university stroke center in whom the treatment plan included transition from acute to chronic anticoagulation. The LMWH group was contrasted with the preceding 24 patients transitioned to warfarin with IVUH at the same center.

Results—Fewer patients in the LMWH bridging therapy group experienced neurological worsening than in the IVUH bridging therapy group (2/24 versus 8/24; P=0.033). Fewer total adverse events were noted in the LMWH group than in the IVUH cohort (3 versus 20; P=0.002). Fifteen of the 24 LMWH patients (62.5%) were discharged while still receiving LMWH and completed transition to warfarin as outpatients, receiving an average of 3.6 days of outpatient transitional therapy. In these 15 patients, use of LMWH was associated with a net savings of $2197 per patient.

Conclusions—In this pilot cohort with subacute cerebral ischemia, bridging LMWH appeared to be safer than bridging IVUH and was associated with reduced hospital stay and reduced total cost of care.

Key Words: anticoagulants • atrial fibrillation • costs and cost analysis • heparin

This article has been cited by other articles:

				M. Marietta, M. Bertesi, N. Rozzi, M. C. Cano, S. Vallone, C. Cappi, S. Pozzi, and G. Torelli Low-Molecular-Weight Heparin for Vertebral Artery Dissection Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 179 - 181. [Abstract] [PDF]